title: Strategies for the development of new PPAR agonists in diabetes.
abstract: Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.
authors.affiliation: Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA. matt.cavender@gmail.com
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Cavender
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
authors.forename: A Michael
authors.initials: AM
authors.lastname: Lincoff
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D048909:Diabetes Complications / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D047492:Peroxisome Proliferator-Activated Receptors